Westwood Holdings Group’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Sell
21,453
-2,462
-10% -$130K 0.01% 349
2025
Q4
$1.25M Sell
23,915
-1,204
-5% -$72.1K 0.01% 365
2025
Q3
$1.63M Sell
25,119
-5,395
-18% -$310K 0.01% 352
2025
Q2
$1.48M Sell
30,514
-8,552
-22% -$331K 0.01% 357
2025
Q1
$1.33M Sell
39,066
-14,036
-26% -$595K 0.01% 346
2024
Q4
$2.09M Buy
53,102
+8,120
+18% +$383K 0.02% 317
2024
Q3
$2.11M Buy
44,982
+7,607
+20% +$386K 0.01% 329
2024
Q2
$2.02M Buy
37,375
+22,516
+152% +$1.3M 0.01% 315
2024
Q1
$1.01M Sell
14,859
-30,473
-67% -$2.18M 0.01% 358
2023
Q4
$2.84M Sell
45,332
-129,856
-74% -$7.18M 0.02% 282
2023
Q3
$7.95M Buy
175,188
+85,158
+95% +$4.4M 0.07% 204
2023
Q2
$5.05M Sell
90,030
-3,509
-4% -$199K 0.05% 249
2023
Q1
$4.23M Buy
93,539
+63,360
+210% +$3.08M 0.04% 260
2022
Q4
$1.23M Sell
30,179
-2,150
-7% -$114K 0.01% 336
2022
Q3
$2.11M Sell
32,329
-9,945
-24% -$721K 0.03% 260
2022
Q2
$2.57M Buy
42,274
+23,582
+126% +$1.39M 0.03% 269
2022
Q1
$1.17M Buy
18,692
+9,439
+102% +$593K 0.01% 345
2021
Q4
$701K Sell
9,253
-10,040
-52% -$877K 0.01% 366
2021
Q3
$2.16M Buy
19,293
+9,310
+93% +$1.17M 0.02% 280
2021
Q2
$1.62M Buy
+9,983
New +$1.21M 0.02% 307

Other funds holding CRSP

Westwood Holdings Group's CRSP Position: Q1 2026 in Review

Westwood Holdings Group reduced its CRISPR Therapeutics (CRSP) stake by 10% in Q1 2026, selling an estimated $130K and leaving 21,453 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #349.

Westwood Holdings Group first reported a position in CRSP in Q2 2021 and has held it in 20 quarters since. The position peaked at $7.95M in Q3 2023. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Westwood Holdings Group held 21,453 shares of CRISPR Therapeutics worth $1.02M as of Q1 2026.
  • Westwood Holdings Group sold 2,462 CRISPR Therapeutics shares in Q1 2026, an estimated $130K.
  • CRISPR Therapeutics made up 0.01% of Westwood Holdings Group's portfolio in Q1 2026, its #349 holding.
  • Westwood Holdings Group first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Westwood Holdings Group's CRISPR Therapeutics position peaked at $7.95M in Q3 2023.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Westwood Holdings Group's 13F filing for Q1 2026, filed 15 May 2026.